Department of Interdisciplinary Life Sciences, Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, University of Vienna, Vienna, Austria.
Institute of Comparative Medicine, Columbia University, New York, NY, United States of America.
PLoS One. 2024 Feb 20;19(2):e0297375. doi: 10.1371/journal.pone.0297375. eCollection 2024.
The harm-benefit analysis (HBA) is a cornerstone of the European Directive 2010/63/EU (the Directive). The Directive regulates the care and handling of animals used for scientific purposes in the European Union (EU). Since its implementation, there has been ongoing debate around the practical applicability of the HBA for research project review processes. The objectives of this study are to analyze the operationalization of HBA in EU member states and investigate the consistency of HBA's implementation in terms of national legislation and available policy documents. To meet these objectives, we evaluated the transposition of the HBA requirement into national legislation. We also conducted a comprehensive comparative cross-national analysis of all guidance documents pertinent to HBA. The results of our study show that there are (1) deficits in the transposition of the HBA requirement into national laws, (2) significant discrepancies in available policy documents relating to HBA, and (3) insufficiently consistent implementations of HBA in European countries.
危害-利益分析(HBA)是欧洲指令 2010/63/EU(指令)的基石。该指令规定了在欧盟(EU)内用于科学目的的动物的护理和处理。自实施以来,关于 HBA 在研究项目审查过程中的实际适用性一直存在争议。本研究的目的是分析欧盟成员国中 HBA 的运作情况,并调查国家立法和可用政策文件中 HBA 实施的一致性。为了实现这些目标,我们评估了 HBA 要求在国家立法中的转化情况。我们还对所有与 HBA 相关的指导文件进行了全面的跨国比较分析。我们的研究结果表明,(1)HBA 要求在国家法律中的转化存在缺陷,(2)与 HBA 相关的可用政策文件存在重大差异,以及(3)HBA 在欧洲国家的实施不够一致。